期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
Transcriptomic and metabolomic analysis of the effects of Zhenwu decoction on kidney yang deficiency pattern in chronic kidney disease
1
作者 Pengfei Zheng Yunhua Liu +5 位作者 Xinjiang Zhang Tingting Jiao Yingjie Wu Mengmeng Zhang Xinxue Zhang Zongjiang Zhao 《Journal of Traditional Chinese Medical Sciences》 CAS 2023年第2期228-243,共16页
Objective:To explore the kidney yang deficiency pattern(KYDP)in a chronic kidney disease(CKD)rat model and the mechanisms underlying the effects of Zhenwu decoction(ZWD)by conducting tran-scriptomic and metabolomic an... Objective:To explore the kidney yang deficiency pattern(KYDP)in a chronic kidney disease(CKD)rat model and the mechanisms underlying the effects of Zhenwu decoction(ZWD)by conducting tran-scriptomic and metabolomic analyses.Methods:Adriamycin(ADR)combined with hydrocortisone(HC)was used to induce CKD with KYDP in rats.ADR was injected into the tail vein twice.HC was injected intramuscularly for 8 weeks.ZWD was administered by gavage for 8 weeks.The general condition was observed,24-h urine protein was detected,serum corticosterone,triiodothyronine,thyroxine,TSH,testosterone,cAMP,and cGMP levels were determined,and pathological analysis was conducted.Transcriptomic and metabolomic analyses were conducted to screen differentially expressed genes(DEGs),differentially expressed metabolites(DEMs),and differentially expressed pathways(DEPs).The core DEMs and DEGs were input to Metab-oanalyst 5.0 to identify the pathways affected by ZWD.Results:In the HC group,KYDP symptoms were observed.Compared with control group,the levels of 24-h urine protein,TSH,and cGMP significantly increased(all P<0.01),and corticosterone,triiodothyronine,thyroxine,and cAMP significantly decreased(all P<0.01)in the HC group.After ZWD intervention,the levels of above-mentioned indicators could be reversed to some extent.Pathological analysis in the HC group revealed kidney lesions.DEGs in the ZWD group were mainly associated with pathways such as nucleotide synthesis and endocrine pathways.In the ZWD group,differences in biosynthesis of unsat-urated fatty acids and butanoate metabolism were observed.The following pathways were significantly affected by ZWD:arachidonic acid metabolism,valine,leucine,and isoleucine biosynthesis,linoleic acid metabolism,and alpha-linolenic acid metabolism.Conclusion:ZWD can be used to treat KYDP in CKD through regulating arachidonic acid metabolism,valine,leucine,and isoleucine biosynthesis,linoleic acid metabolism,and alpha-linolenic acid metabolism. 展开更多
关键词 Chronic kidney disease kidney yang deficiency pattern Zhenwu decoction TRANSCRIPTOMICS Metabolomics
下载PDF
肾病Ⅰ、Ⅱ、Ⅲ号方分阶段辨证治疗难治性肾病综合征的研究 被引量:4
2
作者 黄仁发 梁群卿 +8 位作者 赖虹伊 林心如 向少伟 唐丽萍 龙韵 胡维 谭嘉臻 葛旭 马晓露 《现代中西医结合杂志》 CAS 2016年第1期4-6,10,共4页
目的观察肾病Ⅰ、Ⅱ、Ⅲ号方分阶段治疗难治性肾病综合征的临床疗效。方法将76例难治性肾病综合征患者随机分为2组,对照组给予常规西医治疗,治疗组在对照组治疗基础上分阶段予以肾病Ⅰ、Ⅱ、Ⅲ号方治疗。观察2组治疗前后24h尿蛋白定量... 目的观察肾病Ⅰ、Ⅱ、Ⅲ号方分阶段治疗难治性肾病综合征的临床疗效。方法将76例难治性肾病综合征患者随机分为2组,对照组给予常规西医治疗,治疗组在对照组治疗基础上分阶段予以肾病Ⅰ、Ⅱ、Ⅲ号方治疗。观察2组治疗前后24h尿蛋白定量、血清白蛋白(ALB)、血胆固醇(TC)、三酰甘油(TG)、血尿素氮(BUN)、血肌酐(SCr)、血常规及水肿、乏力、腹胀、腰酸证候积分变化情况,统计2组疾病疗效及疾病缓解的时间、中医证候疗效及感染、肝损害情况。结果治疗后24 h 2组尿蛋白定量、ALB、TC、TG、BUN、SCr均较治疗前明显改善(P均<0.05),且治疗组24 h尿蛋白定量、ALB、TC、TG改善情况均明显优于对照组(P均<0.05);治疗后2组BUN、SCr比较差异无统计学意义。治疗后2组各项中医证候积分均较治疗前明显改善(P均<0.05),且治疗组改善情况明显优于对照组(P均<0.05)。治疗组疾病缓解率和中医证候总有效率均明显高于对照组(P均<0.05),感染和肝损害发生率均明显低于对照组(P均<0.05)。结论肾病Ⅰ、Ⅱ、Ⅲ号方联合常规西医治疗难治性肾病综合征疗效好,且可减少感染及肝损害的发生。 展开更多
关键词 难治性肾病综合征 肾病号方 肾病Ⅱ号方 肾病Ⅲ号方
下载PDF
四妙勇安汤加减治疗2型糖尿病合并冠心病的疗效观察及对血清ApoB、ApoA-Ⅰ的影响 被引量:13
3
作者 邵锦华 贺乐 +3 位作者 孙瑾 汪宁 叶楠 尤菲 《辽宁中医杂志》 CAS 2020年第11期123-126,共4页
目的研究四妙勇安汤加减联合常规治疗对2型糖尿病(type 2 diabetes mellitus,T2DM)合并冠心病(coronary heart disease,CHD)患者的疗效及对血清载脂蛋白A-Ⅰ(apolipoprotein A-Ⅰ,ApoA-Ⅰ)和载脂蛋白B(apolipoprotein B,ApoB)的影响。... 目的研究四妙勇安汤加减联合常规治疗对2型糖尿病(type 2 diabetes mellitus,T2DM)合并冠心病(coronary heart disease,CHD)患者的疗效及对血清载脂蛋白A-Ⅰ(apolipoprotein A-Ⅰ,ApoA-Ⅰ)和载脂蛋白B(apolipoprotein B,ApoB)的影响。方法选取2017年4月—2019年10月期间该院收治的84例T2DM合并CHD患者,采用随机数字表法分为对照组和观察组,每组42例。对照组给予常规西药治疗,观察组在对照组的基础上给予四妙勇安汤加减,治疗28 d后评价两组患者的疗效及安全性,分别于治疗前后检测两组患者的血糖相关指标(FBG、HbA1c、FINS)、血脂相关指标(TC、TG、LDL-C、HDL-C)及血清中ApoA-Ⅰ和ApoB的浓度。结果两组患者经治疗均取得了良好的疗效,观察组总有效率高于对照组(P<0.05);治疗后两组患者血糖及血脂相关指标均得到改善(P<0.05),且观察组均优于对照组(P<0.05);治疗后两组患者血清ApoA-Ⅰ浓度均升高、ApoB浓度均降低(P<0.05),且与对照组相比,观察组ApoA-Ⅰ浓度较高、ApoB浓度较低(P<0.05);两组患者均未见明显不良反应。结论四妙勇安汤加减可有效提高常规西药对T2DM合并CHD患者的疗效,升高血清ApoA-Ⅰ和降低ApoB的浓度,降低ApoB/ApoA-Ⅰ的比例,且无明显不良反应。 展开更多
关键词 四妙勇安汤 2型糖尿病 冠心病 载脂蛋白A- 载脂蛋白B
下载PDF
Qianjin Wenwu decoction suppresses renal interstitial fibrosis by enhancing the degradation of extracellular matrix in mice with unilateral ureteral obstruction
4
作者 JIN Chengshan WU Xiaotian +5 位作者 YOU Yue WANG Yuing WU Jing ZUO Along ZHENG Yan GUO Jianpeng 《Chinese Journal of Natural Medicines》 SCIE CAS CSCD 2023年第4期253-262,共10页
Diabetic kidney disease(DKD)is the most common complication of diabetes mellitus(DM).Qianjin Wenwu decoction(QWD),a well-known traditional Korean medicine,has been used for the treatment of DKD,with satisfactory thera... Diabetic kidney disease(DKD)is the most common complication of diabetes mellitus(DM).Qianjin Wenwu decoction(QWD),a well-known traditional Korean medicine,has been used for the treatment of DKD,with satisfactory therapeutic effects.This study was designed to investigate the active components and mechanisms of action of QWD in the treatment of DKD.The results demonstrated that a total of 13 active components in five types were found in QwD,including flavonoids,flavonoid glycosides,phenylpropionic acids,saponins,coumarins,and lignins.Two key proteins,TGF-β1 and TIMP-1,were identified as the target proteins through molecular docking.Furthermore,QWD significantly suppressed Scr and BUN levels which increased after unilateral ureteral obstruction(UUO).Hematoxylin&eosin(H&E)and Masson staining results demonstrated that QWD significantly alleviated renal interstitial fibrosis in UUO mice.We also found that QWD promoted ECM degradation by regulating MMP-9/TIMP-1 homeostasis to improve renal tubulointerstitial fibrosis and interfere with the expression and activity of TGF-βl in DKD treatment.These findings explain the underlying mechanism of QWD for the treatment of DKD,and also provide methodological reference for investigating the mechanism of traditional medicine in the treatment of DKD. 展开更多
关键词 QianJin Wenwu decoction(QWD) Diabetic kidney disease(DKD) Pharmacodyamic material basis Molecular docking TGF-β1 Extracellular matrix(ECM)
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部